Haplotypes of the fibrinogen gene and cerebral small vessel disease: The Rotterdam scan study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 7, 2008, Pages 799-803

  Van Oijen, M ^a   Cheung, E Y L ^a   Geluk, C E M ^a   Hofman, A ^a   Koudstaal, P J ^a   Breteler, M M B ^a   De Maat, M P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

ADULT; AGED; ARTICLE; BRAIN BLOOD VESSEL; BRAIN DAMAGE; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER;

AGED; AGED, 80 AND OVER; BRAIN INFARCTION; COHORT STUDIES; FEMALE; FIBRINOGEN; HAPLOTYPES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NETHERLANDS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VARIATION (GENETICS);

EID: 46249102440     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.113035     Document Type: Article

References (35)

1. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-22.
2. van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005;112:900-5.
3. Markus HS, Hunt B, Palmer K, et al. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005;36:1410-14.
4. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.
5. van Oijen M, Witteman JC, Hofman A, et al. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005;36:2637-41.
6. Cooper AV, Standeven KF, Ariens RA. Fibrinogen gamma-chain splice variant gamma′ alters fibrin formation and structure. Blood 2003;102:535-40.
7. Lim BC, Ariens RA, Carter AM, et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003;361:1424-31.
8. de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000;47:145-51.
9. Hofman A, Grobbee DE, de Jong PT, et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22.
10. Clauss A. Rapid physiological coagulation method in determination of fibrinogen (Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens). Acta Haematol 1957;17:237-46.
11. Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21-5.
12. Bots ML, van Swieten JC, Breteler MM, et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet 1993;341:1232-7.
13. Verschuur M, de Jong M, Felida L, et al. A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent -148C/T polymorphism. J Biol Chem 2005;280:16763-71.
14. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003;55:56-65.
15. Epstein MP, Satten GA. Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 2003;73:1316-29.
16. de Leeuw FE, de Groot JC, Oudkerk M, et al. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 1999;46:827-33.
17. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
18. Schmidt R, Fazekas F, Hayn M, et al. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci 1997;152:15-21.
19. Martiskainen M, Pohjasvaara T, Mikkelsson J, et al. Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke 2003;34:886-91.
20. van Goor MP, Gomez-Garcia EB, Leebeek FW, et al. The -148 C/T fibrinogen gene polymorphism and fibrinogen levels in ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry 2005;76:121-3.
21. Rubattu S, Di Angelantonio E, Nitsch D, et al. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thromb Haemost 2005;93:1095-100.
22. Gao X, Yang H, Zhiping T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. Neurosci Lett 2006;398:172-7.
23. Drenos F, Miller GJ, Humphries SE. Increase of plasma fibrinogen levels and variability with age in a sample of middle aged healthy men. Ann Hum Genet 2007;71:43-53.
24. Mannila MN, Eriksson P, Lundman P, et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005;93:570-7.
25. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma′ levels. Blood 2005;106:4176-83.
26. Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999;99:2423-6.
27. Carter AM, Catto AJ, Kohler HP, et al. Alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000;96:1177-9.
28. Drouet L, Paolucci F, Pasqualini N, et al. Plasma gamma′/gamma fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Blood Coagul Fibrinolysis 1999;10(Suppl 1):S35-9.
29. Lovely RS, Falls LA, Al-Mondhiry HA, et al. Association of gammaA/gamma′ fibrinogen levels and coronary artery disease. Thromb Haemost 2002;88:26-31.
30. Mannila MN, Eriksson P, Ericsson CG, et al. Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction. Thromb Haemost 2006;95:420-7.
31. Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003;107:2326-30.
32. de Leeuw FE, De Groot JC, Oudkerk M, et al. Aortic atherosclerosis at middle age predicts cerebral white matter lesions in the elderly. Stroke 2000;31:425-9.
33. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001;70:9-14.
34. de Leeuw FE, de Groot JC, Oudkerk M, et al. Atrial fibrillation and the risk of cerebral white matter lesions. Neurology 2000;54:1795-801.
35. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997;28:652-9.